Date: Aug 02, 2013 Source: Yahoo Finance (
click here to go to the source)
SCOTTSDALE, AZ--(Marketwired - Aug 2, 2013) - Hope Pharmaceuticals today announced that the United States Patent and Trademark Office issued U. S. patent no. 8,496,973, titled "Sodium Thiosulfate-Containing Pharmaceutical Compositions." The patent relates to the active pharmaceutical ingredient, its formulation and use in the company's Nithiodote and Sodium Thiosulfate Injection products. The patent is set to expire in March 2031, absent any extension.
Hope Pharmaceuticals manufactures Sodium Thiosulfate Injection which is formulated with the new sodium thiosulfate pentahydrate material.
The United States Food and Drug Administration (FDA) approved Hope Pharmaceuticals' Sodium Thiosulfate Injection for sequential use with Sodium Nitrite Injection for the treatment of acute cyanide poisoning that is judged to be life-threatening. Sodium Thiosulfate Injection is co-packaged with Sodium Nitrite Injection in a kit called Nithiodote. It is also available as an individually-packaged medication. Prescribing information for Nithiodote and Sodium Thiosulfate Injection is available online at www.nithiodote.com and www.thiosulfate.info, respectively.
Hope Pharmaceuticals is currently the only supplier of Sodium Thiosulfate Injection in the United States.
